arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ImmunityBio, Inc.

IBRX
$8.01 ▼ -0.93 (-10.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
52 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
48
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

ImmunityBio, Inc. faces fundamental challenges. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $8.4B
Dividend Yield —
Revenue Growth 93.9% ↘
Op. Margin -120.4% ↗
ROIC 5.9% ↘
FCF / Share $-0.07 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$51.24M
↑ +93.9% —
Net Income Profit after all expenses
$-230.38M
↓ -148.9% —
Operating Margin Operating profit as % of sales
-120.4%
↑ +23.7% 0th
FCF / Share Free cash flow per share
$-0.07
↑ +11.2% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Returns ↓
98
Financial Health ↑
38
Cash Quality →
59

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters